Outcome of Board Meeting

Date: 13.08.2026 To To The Manager The Manager Listing Compliance Listing Compliance Bombay Stock Exchange Limited National Stock Exchange of India P.J Towers, Dalal Street, Limited (NSE) Mumbai-400 001 Exchange Plaza, Bandra Kurla Complex, Maharashtra, India Bandra East, Mumbai – 400051 SCRIP CODE: 543919 NSE SYMBOL: MKPL Subject: Outcome of the Board Meeting held today i.e. on 13th August, 2026 Dear Sir/Madam, With reference to the above, we hereby submit / inform that the Board of Directors (“the Board”) of the Company at its meeting held today i.e. on 13th August, 2026: 1. approved the Un-Audited Financial Results of the Company for the quarter ended 30th June, 2026. The said Un-Audited Financial Results prepared in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015 together with the Limited Review Report (LRR) are enclosed. These results are also being uploaded on the Company’s website at www.mkproteins.in. 2. took note of the resignation submitted by Ms. Laxmi Mandal (DIN: 05287716), Independent Director of the Company on 12th August 2026. The disclosure as required under Regulation 30 read with Para A(7B) of Part A of Schedule III of SEBI (LODR) Regulation, 2015 is already submitted to the stock exchanges. The meeting of the Board of Directors commenced at 03:30 P.M. and concluded at 04:30 P.M. You are requested to take the same on your record. Thanking you, Yours Faithfully, FOR M K PROTEINS LIMITED Neha Aggarwal Company Secretary cum Compliance Officer M. K. Proteins Limited Naraingarh Road, Village Garnala, Ambala City(Haryana), India - 134003 T : 0171-2679358 I W: www.mkproteins.in I E: compliancemkproteins@gmail.com CIN : L15500HR2012PLC046239| ISIN : INE964W01021 V\( SUBHASH SAJAL & ASSOCIATES INDIA Chartered Accountants 1766, New Christian Colony, *A Peer Reviewed Firm* Near Civil Hospital, Jagadhri — 135003 M: 94166-84636, 98962-57600 Email: smittalca504@gmail.com smittalca@rediffmail.com Limi i n ndal rly an r financial Results of the Company Pursuant to the Requlation 33 of the SEBI (Listing Obligations and iscl re R ir n R lations 2015 The Board of Directors, M. K. Proteins Limited 1. We have audited the accompanying statement of unaudited quarterly standalone financial results of M. K. Proteins Limited (“the Company”) for the quarter ended June 30, 2026, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 (hereafter referred to as “the Regulations”), to the Stock Exchange. 2. The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, interim financial reporting (Ind AS 34) prescribed under section 133 of the Companies Act, 2013 read with rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and read with SEBI Circular No. CIR/CFD/FAC/62/2076 dated July 05, 2016 is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these Financial Statements based on our review. 3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited quarterly Financial Results, prepared in accordance with applicable accounting standards specified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies [Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI( Listing Obligations and Disclosure Requirements) Regulations,2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement. Place: Yamunanagar For Subhash Sajal and Associates Chartered Accountants Firm Registration No. 018178N Date: 13 August 2026 Chagtered \ 2. ufi\\&u Accountants FRN: 018178N CA SAJAL MITTAL (PARTNER) Membership No.: 576124 UDIN: 26576124GJDJMB5031 M. K. PROTEINS LIMITED Regd. Office: Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003 T: 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com CIN: L1SS00HR2012PLC046239 | ISIN: INE964W01021 (Rs. In Lacs) QUARTER ENDED YEAR ENDED 30062026 3103206 30063025 31032026 31032025 (UNAUDITED), (AUDITED) | (UNAUDITED) | (AUDITED) | (AUDITED) 1. [Revenue a) [Revenue from Operation (Net) 11516.12 1459406 1149460 3828752 26770.60 b) [Other Income 0.00 11.80 0.00 2594 47.66 Sub-Total “1* 11516.12 14605.86 1199460 3831346 26818 26 2. [Expenditure @) [Cost of Material Consumed 9087.62 965140 8770.74 2864884 1667436 b) [Purchase of Stock-in-Trade 123455 1991 87 168876 736924 514941 ©) [Change in inventories of Finished Goods, 34627 1675.69 14631 (717.06) 214627 [Work-in-progress and Stock-in-Trade ) [Employees Benefits Expenses 7844 11096 5370 30277 27452 ©) [Manufacturing, Operating _and _Other 51778 91438 28407 154198 128293 [Expenses ) [Finance Costs 5194 79.03 70.16 18520 11050 [Depreciation and Amortization Expenses 478 1079 1035 43.63 3517 [Sub-Total 2~ 1133138 1443412 1102409 3737460 2567316 3 [Profit(Loss) before Exceptional, 18474 17174 47051 938.86 114510 [Extraordinary items and Tax [ 1-2] 4 [Exceptional items 000 0,00 0,00 0.00 0.00 5 [Profit/(Loss) before Extraordinary fiems 8474 7174 77051 93886 1145.10 Jand Tax [3 4] 6 [Extraordinary liems 0.00 0.00 000 0.00 0,00 7_[Profit(Loss) before Tax [5—6] 18474 17174 470,51 938,86 114510 8 [Tax Expenses a) [Provision for Current Tax 4593 5726 1815 2679 30186 b) [Provision for Defemed Tax 057 065 o4 52l 3.50 Liability/(Adjustment) ) [Prior Year Taxes 0,00 0.00 000 396 0.00 Sub-Total “§" 46,50 5791 119,19 25596 30536 9" [Profit(Loss) for the Period from continuing 3824 JEES) 35132 682.90 83974 perations [ 7 - 8] 10 [Profit(Loss) for the period from 000 0.00 0.00 0.00 0,00 Discontinuing operations before tax 11_[Tax expenses of Discontinuing operations 0,00 000 0,00 000 0.00 12 [Profit/(Loss) from Discontinuing operations. 0,00 0,00 0.00 0.00 0.00 After Tax) [10 1] 13 [Profit/(Loss) for the period [9 = 12] 13824 1383 35132 68290 83974 14 [Other Comprehensive Income net of taxes @) [() Amount of items that will not be 0,00 072 000 073 [O5) reclassified to profit and loss I(( ni oi t) bI en c ro em cle a ssT ia fx ie d re tl o at pi rn og f it to a ndi te lm os s s that will 0.00 018 0.00 018 (0.38) ) [(D) Amount of items that will be reclassified 0.00 0,00 0.00 0,00 0.00 o profit and loss i) Income Tax relating to items that will be 000 000 0.00 0,00 000 Ireclassified to profit and loss [Sub- Total =14~ 0.00 053 0,00 054 @13) 15" [Total comprehensive Income for the Period 13824 1437 35132 68344 83861 13414] 16_|Earnings per share (refer Note 7) ) [Eamings per Equity Share for confmuing loperations lB ca os ni tc i nuine ga mi opn eg rs a/ t( iL oo ns ss ) per sharc from 0.04 5] 0.09 018 022 l[ cD oil nu tt ie nd u ing e oa pr en ri sn tg i/ o( nLo ss s) per share from 004 003 009 018 022 ) [Earnings per Equity Share for discontinuing operations Basic carning/(Loss) per share from 0.00 0.00 0,00 0,00 0.00 discontinuing [Showing first 8,000 characters — download PDF for full document]